Back

Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial

European Heart Journal

6 March 2024
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease
31 August 2025
thumbnail
Webinar
Focus on percutaneous short-term ventricular assist devices: joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices - Part 3. PVAD in right and biventricular failure
8 March 2022
thumbnail
Congress Presentation
Right ventricle function improvement with sacubitril/valsartan therapy
22 May 2023
thumbnail
Congress Session
Transforming heart failure care: unlocking new pathways
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources